digital currency site Overview

By 2029, China will build about 10,000 superior specialties of traditional Chinese medicine. According to state administration of traditional chinese medicine, China will promote the construction of superior specialties of traditional Chinese medicine at different levels to further improve the clinical efficacy of traditional Chinese medicine. By 2029, the overall scale of superior specialties of traditional Chinese medicine will reach about 10,000. Recently, state administration of traditional chinese medicine issued opinions on accelerating the construction of superior specialties of traditional Chinese medicine, and put forward the requirements of strengthening the planning and layout of superior specialties of traditional Chinese medicine and promoting the construction of superior clusters of traditional Chinese medicine. (CCTV News)Mengke Pharmaceutical Co., Ltd.: The new packaging of Contizontamide tablets will be on the market soon. Mengke Pharmaceutical Co., Ltd. announced that the company has launched Contizontamide tablets with new packaging specifications, and a box of 12 tablets will be on the market soon. Contizontamide tablet is a new class 1 oxazolidinone antibacterial drug with global intellectual property rights. It was approved by National Medical Products Administration, China on June 1st, 2021 for the treatment of complex skin and soft tissue infections.Reuters survey: In December, the Bank of England decided to keep interest rates unchanged or cut interest rates by 100 basis points next year. All 71 economists surveyed during December 6-11 predicted that the Bank of England would keep its target interest rate unchanged at 4.75% at its meeting on December 19. Among the economists who predict the interest rate outlook until the end of 2025, about 54% (36 out of 67) expect to cut interest rates by 100 basis points by the end of next year, another 17 expect to cut interest rates by at least 125 basis points, and 14 expect to cut interest rates by at most 75 basis points.

Huaxin Securities: China Unicom's operating income grew steadily and maintained its "buy" rating. Huaxin Securities Research Report pointed out that since the beginning of this year, China Unicom (600050.SH) has seen steady growth in operating income, rapid improvement in profitability, steady expansion of user scale and continuous consolidation of network foundation, laying a more solid foundation for high-quality development of enterprises. Communication and digital intelligence services are driven by two wheels, injecting vitality into the company's performance. Looking forward to the whole year, the company will adhere to the general tone of steady progress, promote the network to be new, technology to be new and service to be new, strive to achieve the performance goal of steady growth of operating income and double-digit growth of profits throughout the year, take greater steps in high-quality development, and accelerate the construction of a world-class science and technology service enterprise with global competitiveness. With the gradual expansion of user scale and the drive of digital transformation, the company will benefit from the continuous improvement of revenue and profit and maintain the "buy" investment rating.Schlegel, Governor of the Swiss National Bank: Since the last interest rate decision, the inflation rate has been lower than expected. The development of the Swiss franc is still an important factor.US Treasury Secretary Yellen: The oil market is well supplied and the price is relatively low. US Treasury Secretary Yellen said that the oil market is well supplied and the price is relatively low. Russia has invested a lot of money in its fleet to avoid the western oil price cap sanctions.

Tschudin, member of the management Committee of the Swiss National Bank: Due to the monetary easing policy, Swiss economic growth is expected to pick up slightly next year. Overseas developments are the main risks facing the Swiss economy.The monkeypox vaccine with independent intellectual property rights in China was approved for clinical use. On December 10th, the monkeypox vaccine jointly developed by China Bio-Beijing Institute of Biological Products and China Center for Disease Control and Prevention received the approval notice of drug clinical trial issued by National Medical Products Administration, and it was registered and classified as Class 1.2 innovative vaccine. The vaccine is an innovative vaccine independently developed by scientists in China with completely independent intellectual property rights, which is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in China. (China Biology)Turkish Defense Ministry source: Syrian allies continue to advance in northern Syria to "eliminate terrorism".